Future Virology. 2013;8(1):1-2. During the global 2002/2003 SARS pandemic, many foundations, pharmaceutical companies and governments provided abundant funds to support the development of anti-SARS ...

Expert Rev Vaccines. 2009;8(7):887-898. Severe acute respiratory syndrome (SARS) caused thousands of human infections worldwide and hundreds of deaths in just a few months, and severely impacted the ...

Most vaccines are designed to provide immunity against just one pathogen. Vaccines for chicken pox (caused by varicella-zoster virus) were only developed to fight that one disease, for example. But in ...

Higher immune responses were elicited by mRNA-1083 than high-dose quadrivalent inactivated influenza vaccine for all 4 influenza strains and high-dose quadrivalent inactivated influenza vaccine for 3 ...

Since SARS-CoV-2 is here to stay, it is important to assess how our understanding of this virus has changed post-pandemic. Dr. Jamie Guenthoer, a staff scientist in the Overbaugh lab at Fred ...

When SARS struck more than 8,000 people and killed nearly 800 in the spring of 2003, the world clamored to know when a vaccine against the deadly virus would come to the rescue. Vaccine manufacturers ...

Harnessing the power of a single dose, this innovative vaccine offers a potent defense against both current and future COVID-19 threats. Study: A single-dose intranasal live-attenuated codon ...

"We do believe we should start with the development of vaccine, and there are quite a few companies going ahead," said Klaus Stöhr, a World Health Organization (WHO) virologist and its chief scientist ...

An experimental vaccine based on a critical piece of the SARS virus protects mice from SARS infection, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the ...